FRLN - Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28 revenue of $0.62M
2023-08-15 07:02:50 ET
More on Freeline Therapeutics
- Freeline, Forcefield team up to develop gene therapies for heart diseases
- Freeline gains as NEJM publishes long-term data for hemophilia therapy
- Freeline begins dosing patients in confirmatory trial to treat hemophilia B
- Freeline slips after disclosing noncompliance with Nasdaq listing rule
- Seeking Alpha’s Quant Rating on Freeline Therapeutics
- Earnings data for Freeline Therapeutics
For further details see:
Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M